Innovent Bio Grants Roche Exclusive Global Rights to ADC Targeting DLL3

MT Newswires Live

Jan 02, 2025

Innovent Biologics (HKG:1801) granted Roche exclusive global rights to develop, manufacture, and sell IBI3009, a DLL3-targeted antibody-drug conjugate (ADC) candidate.

This collaboration aims to bring treatment options to patients with advanced small-cell lung cancer (SCLC), according to a Thursday filing with the Hong Kong Exchange.

Under the deal, Innovent and Roche will partner on the early-stage development of this ADC candidate, after which Roche will take over full development.

Innovent will receive $80 million in upfront payments and be eligible for up to $1 billion in milestone payments, along with tiered royalties on net sales, the filing stated.

IBI3009 targets DLL3, an antigen significantly overexpressed in certain cancers, particularly SCLC and other neuroendocrine tumors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2500999346"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2500999346\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2500999346?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-02 13:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500999346","market":"nz","top_or_hot":-1,"title":"Innovent Bio Grants Roche Exclusive Global Rights to ADC Targeting DLL3","media":"MT Newswires Live","content":"<html><body><p> Innovent Biologics (HKG:1801) granted Roche exclusive global rights to develop, manufacture, and sell IBI3009, a DLL3-targeted antibody-drug conjugate (ADC) candidate.</p><p>This collaboration aims to bring treatment options to patients with advanced small-cell lung cancer (SCLC), according to a Thursday filing with the Hong Kong Exchange.</p><p>Under the deal, Innovent and Roche will partner on the early-stage development of this ADC candidate, after which Roche will take over full development.</p><p>Innovent will receive $80 million in upfront payments and be eligible for up to $1 billion in milestone payments, along with tiered royalties on net sales, the filing stated.</p><p>IBI3009 targets DLL3, an antigen significantly overexpressed in certain cancers, particularly SCLC and other neuroendocrine tumors.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Bio Grants Roche Exclusive Global Rights to ADC Targeting DLL3</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Bio Grants Roche Exclusive Global Rights to ADC Targeting DLL3\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-02 13:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Innovent Biologics (HKG:1801) granted Roche exclusive global rights to develop, manufacture, and sell IBI3009, a DLL3-targeted antibody-drug conjugate (ADC) candidate.</p><p>This collaboration aims to bring treatment options to patients with advanced small-cell lung cancer (SCLC), according to a Thursday filing with the Hong Kong Exchange.</p><p>Under the deal, Innovent and Roche will partner on the early-stage development of this ADC candidate, after which Roche will take over full development.</p><p>Innovent will receive $80 million in upfront payments and be eligible for up to $1 billion in milestone payments, along with tiered royalties on net sales, the filing stated.</p><p>IBI3009 targets DLL3, an antigen significantly overexpressed in certain cancers, particularly SCLC and other neuroendocrine tumors.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2500999346","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500999346","pubTimestamp":1735794641,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Innovent Biologics (HKG:1801) granted Roche exclusive global rights to develop, manufacture, and sell IBI3009, a DLL3-targeted antibody-drug conjugate (ADC) candidate.This collaboration aims to bring ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","ADC":"艾格里房产","01801":"信达生物","BK1161":"生物科技","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","ADC.AU":"ACDC Metals Ltd","BK1589":"北水核心资产","BK1583":"高瓴概念","BK7095":"多种金属与采矿","BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托"},"translate_title":"信达生物授予罗氏靶向DLL3的ADC全球独家权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC.AU":1,"ADC":1,"01801":0.9},"content_text":"Innovent Biologics (HKG:1801) granted Roche exclusive global rights to develop, manufacture, and sell IBI3009, a DLL3-targeted antibody-drug conjugate (ADC) candidate.This collaboration aims to bring treatment options to patients with advanced small-cell lung cancer (SCLC), according to a Thursday filing with the Hong Kong Exchange.Under the deal, Innovent and Roche will partner on the early-stage development of this ADC candidate, after which Roche will take over full development.Innovent will receive $80 million in upfront payments and be eligible for up to $1 billion in milestone payments, along with tiered royalties on net sales, the filing stated.IBI3009 targets DLL3, an antigen significantly overexpressed in certain cancers, particularly SCLC and other neuroendocrine tumors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}